
    
      This is a Phase 2, open label, study to assess the activity and safety of utrophin modulation
      with SMT C1100 (ezutromid) administered twice-daily orally in ambulatory paediatric male
      participants with DMD.

      This study will be conducted in a multi-centre setting in both the United Kingdom and the
      United States of America and comprises of a Screening and Baseline Phase of up to 28 days, a
      48-week open label Treatment Phase, and either a 30-day Safety Follow up Phase or an optional
      extension phase where study treatment is provided until discontinuation of the program or
      regulatory approvals as applicable.
    
  